An open‐label cluster‐randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID‐19 (ARCHAIC)—Protocol publication
- 19 June 2020
- journal article
- editorial
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 50 (7), e13297
- https://doi.org/10.1111/eci.13297
Abstract
No abstract availableKeywords
Funding Information
- ZonMw (10150062010001)
This publication has 8 references indexed in Scilit:
- Chloroquine and hydroxychloroquine as available weapons to fight COVID-19International Journal of Antimicrobial Agents, 2020
- Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivistsIntensive Care Medicine, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyThe Lancet, 2020
- Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy–treated immunologic nonrespondersBlood, 2011
- A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese AdultsPLoS Neglected Tropical Diseases, 2010
- Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1Clinical Therapeutics, 1995